You are here:
Several risk factors such as thyroid dysfunction and hypertonia have been identified to predispose to cardiovascular disorders; however, the underlying molecular mechanisms are still not completely understood. In our previous work, we described the first in vivo characterization of novel endogenous thyroid hormone derivative, N-acetyl-3-iodothyronamine (NAc-3-T1AM), which is produced by liver and white fat from 3-iodothyronamine. The new hormone increases heart rate and blood pressure potentially by activating β-adrenergic signaling on cardiomyocytes.
The main goal of this research project is to unravel the molecular mechanisms of NAc-3-T1AM biosynthesis and metabolism and β-adrenergic signaling in the heart using novel in vivo and in vitro techniques. Furthermore, we aim to establish a reliable quantification method for NAc-3-T1AM in human serum to study the influence of NAc-3-T1AM on thyroid hormone metabolism, aging and body composition to obtain novel insight into the potential actions of NAc-3-T1AM in whole body physiology. Thus we will enhance our understanding of thyronamine metabolism and action in cardiovascular function with a potentially significant benefit for human health.
Current lab members
- Dr. rer. nat. Carolin Höfig (Junior group leader)
- Gabriele Böhm (Technical assistance)
- Assel Sarsenbayeva (Molecular medicine student)
- Franziska Kugel (MD candidate)
- Rega Qasim Hasan (MD candidate)
- Jasmin Anbelle Schäfer (MD candidate)